Practice Locations

University of Colorado Cancer Center
CU Anschutz Medical Campus
1665 Aurora Ct Aurora, CO 80045


Christopher Lieu, MD

Medical Oncology

Board Certified


Practice Locations

University of Colorado Cancer Center
CU Anschutz Medical Campus
1665 Aurora Ct, Aurora, CO 80045


UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct Aurora, CO 80045


Pancreas & Biliary Multidisciplinary Clinic - Anschutz
1665 Aurora Ct 3rd Floor, Aurora, CO 80045


UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave Aurora, CO 80045


Provider Expertise

Clinical Interest for Patients

I am interested in Gastrointestinal Cancers (Colorectal, Pancreatic, Gastric, Esophageal, Hepatocellular, Gallbladder, Bile Duct, Anal, Carcinoma of Unknown (Primary), Drug Development (Experimental Therapeutics) and Translational Research.

Care Philosophy

We strive to provide patient-focused, personalized, multi-disciplinary care for gastrointestinal (GI) cancers. Our specialized providers in Medical Oncology (chemotherapy and targeted therapies), Surgical Oncology, Radiation Oncology, Pathology, Molecular Pathology, Radiology, Interventional Radiology, Nuclear Medicine, Gastroenterology (both Hepatology and Interventional Endoscopy), Nutrition, and Integrative Medicine work together to achieve the best outcomes for our patients. We have cancer-specific multidisciplinary clinics in pancreas, colorectal, gastroesophageal, liver, and neuroendocrine cancers where patients can meet all of their specialty providers in a single clinic visit. Dr. Lieu joined the University of Colorado School of Medicine faculty in 2011. He trained in internal medicine at the University of Colorado, where he also served as a Chief Medical Resident. Dr. Lieu completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center and served as the Chief Medical Oncology Fellow in 2010. Dr. Lieu currently serves as the co-Director of GI Medical Oncology at the University of Colorado Cancer Center, the Vice-Chair of the National Cancer Institute Colon Cancer Task Force, the FDA Oncologic Drugs Advisory Committee (ODAC), and the National Comprehensive Cancer Network (NCCN) Panel for Neuroendocrine Cancers.


  • Internal Medicine ( 2007 )
  • Medical Oncology ( 2011 )

Conditions & Treatments

  • Cancers

    Biliary Cancer, Cancer Medicine, Cancer Prevention, Colorectal Cancer, Gastroenterologic Cancer (Colon, Stomach, Esophageal, Liver), Pancreatic Cancer

  • Digestive System

    Gastroenterology (Stomach, Bowel, General GI Problems)

Education & Training

Medical Schools

MD, Wake Forest University School of Medicine (2004)

Undergraduate Schools

BS, University of North Carolina–Chapel Hill (NC) (2000)


University of Colorado (University Hospital) Program (2005)

Residency Program

University of Colorado (University Hospital) Program (2008)


University of Texas M D Anderson Cancer Center Program (2011)

Professional Memberships

American Association for Cancer Research, Member

American Society of Clinical Oncology, Member

Arnold P. Gold Foundation, Member

Rocky Mountain Oncology Society, Member

Southwest Oncology Group, Member

Research & Grants


K23CA190949A (2015)

R01CA229259 (2018)

Research Interests for Patients

I am a member of the Developmental Therapeutics (phase I clinical trials) and Gastrointestinal (GI) Medical Oncology Program. These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors. I am interested in resistance mechanisms to targeted therapy in GI cancers, and I was awarded the Conquer Cancer Foundation Career Development Award, NIH K23 grant, and a NIH R01 grant to study targeted therapies in colorectal cancer. I am also investigating novel therapeutic strategies to more effectively treat and prevent colorectal cancer in young adults.

information for referring providers

Referral Contact Phone

(720) 848-0300

Referral Contact Fax


Clinical Interests for Referring Providers

Immunotherapy and targeted therapy clinical trials for patients with colorectal cancer.

Research Interest for Referring Providers

Targeted and immunotherapies for colorectal and GI malignancies, Young-onset colorectal cancer, RAS and BRAF mutated colorectal cancer, Targeted and immunotherapies for pancreatic cancers, Targeted therapies for neuroendocrine cancers